Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients
Sponsor: Peking University People's Hospital
Summary
The purpose of this study is to assess efficacy of gonadotropin-releasing hormone agonist (goserelin) on the preservation of ovarian reserve function in young breast cancer patients treated with (neo)adjuvant chemotherapy by serial measuring ovarian reserve markers (AMH and AFC.etc) before and after chemotherapy and long-term pregnancy outcomes. Meanwhile, to evaluate the safety of this protective approach in young breast cancer patients by disease-free survival (DFS) and overall survival (OS) outcomes.
Official title: Effect of Goserelin on the Protection of Ovarian Reserve During (Neo)Adjuvant Chemotherapy for Young Breast Cancer Patients: A Prospective Cohort Trial
Key Details
Gender
FEMALE
Age Range
18 Years - 45 Years
Study Type
OBSERVATIONAL
Enrollment
349
Start Date
2015-12-25
Completion Date
2024-12-31
Last Updated
2024-12-12
Healthy Volunteers
No
Conditions
Interventions
Goserelin 3.6 MG
In goserelin group, goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration.
Locations (1)
Peking University People's Hospital
Beijing, Beijing Municipality, China